Loading…
Hsp90/p50cdc37 Is Required for Mixed-lineage Kinase (MLK) 3 Signaling
Mixed-lineage kinase 3 (MLK3) is a mitogen-activated protein kinase (MAPK) kinase kinase that activates MAPK pathways, including the c -Jun NH 2 -terminal kinase (JNK) and p38 pathways. MLK3 and its family members have been implicated in JNK-mediated apoptosis. A survey of human cell lines revealed...
Saved in:
Published in: | The Journal of biological chemistry 2004-05, Vol.279 (19), p.19457-19463 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Mixed-lineage kinase 3 (MLK3) is a mitogen-activated protein kinase (MAPK) kinase kinase that activates MAPK pathways, including
the c -Jun NH 2 -terminal kinase (JNK) and p38 pathways. MLK3 and its family members have been implicated in JNK-mediated apoptosis. A survey
of human cell lines revealed high levels of MLK3 in breast cancer cells. To learn more about MLK3 regulation and its signaling
pathways in breast cancer cells, we engineered the estrogen-responsive human breast cancer cell line, MCF-7, to stably, inducibly
express FLAG epitope-tagged MLK3. FLAG·MLK3 complexes were isolated by affinity purification, and associated proteins were
identified by in-gel trypsin digestion followed by liquid chromatography/tandem mass spectrometry. Among the proteins identified
were heat shock protein 90α,β (Hsp90) and its kinase-specific co-chaperone p50 cdc37 . We show that endogenous MLK3 complexes with Hsp90 and p50 cdc37 . Further experiments demonstrate that MLK3 associates with Hsp90/p50 cdc37 through its catalytic domain in an activity-independent manner. Upon treatment of MCF-7 cells with geldanamycin, an ansamycin
antibiotic that inhibits Hsp90 function, MLK3 levels decrease dramatically. Furthermore, tumor necrosis factor α-induced activation
of MLK3 and JNK in MCF-7 cells is blocked by geldanamycin treatment. Our finding that geldanamycin treatment does not affect
the cellular levels of the downstream signaling components, MAPK kinase 4, MAPK kinase 7, and JNK, suggests that Hsp90/p50 cdc37 regulates JNK signaling at the MAPK kinase kinase level. Previously identified Hsp90/p50 cdc37 clients include oncoprotein kinases and protein kinases that promote cellular proliferation and survival. Our findings reveal
that Hsp90/p50 cdc37 also regulates protein kinases involved in apoptotic signaling. |
---|---|
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1074/jbc.M311377200 |